{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:56:49Z","timestamp":1772805409042,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,4,25]],"date-time":"2007-04-25T00:00:00Z","timestamp":1177459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> To evaluate the efficacy, safety and tolerability of octreotide LAR<jats:sup>\u00ae<\/jats:sup> (long\u2010acting repeatable octreotide) in the primary therapy of acromegaly.<\/jats:p><jats:p><jats:bold>Design and patients\u2002<\/jats:bold> Ninety\u2010eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients successfully completed 48\u00a0weeks of the study period, received 12 doses of octreotide LAR 10\u201330\u00a0mg every 4\u00a0weeks, and constituted the population used for this analysis.<\/jats:p><jats:p><jats:bold>Measurements and results\u2002<\/jats:bold> A clinically relevant reduction (i.e. to \u2264\u00a05\u00a0\u00b5g\/l) in mean GH (mGH) was recorded in 72% of patients after 24\u00a0weeks of treatment, and 42% reached a \u2018safe\u2019 GH value (\u2264\u00a02\u00b75\u00a0\u00b5g\/l). At week\u00a048, 16 more patients were considered partial GH responders (GH\u00a0&gt;\u00a02\u00b75\u00a0\u00b5g\/l and \u2264\u00a05\u00a0\u00b5g\/l) and 44% had reached a GH level \u2264\u00a02\u00b75\u00a0\u00b5g\/l. IGF\u20101 levels normalized in 38% and 34% of patients after 24 and 48\u00a0weeks of treatment, respectively. At study completion, 10 patients (14\u00b77%) who had not normalized their IGF\u20101 levels had achieved at least a 50% decrement in this marker. In eight microadenoma patients, tumour volume decreased from a mean baseline level of 298\u00a0\u00b1\u00a0145\u00a0mm<jats:sup>3<\/jats:sup> to 139\u00a0\u00b1\u00a094\u00a0mm<jats:sup>3<\/jats:sup> after 24\u00a0weeks and to 99\u00a0\u00b1\u00a070\u00a0mm<jats:sup>3<\/jats:sup> after 48\u00a0weeks of therapy. In 60 patients with macroadenoma, the corresponding values were 3885\u00a0\u00b1\u00a05077\u00a0mm<jats:sup>3<\/jats:sup> at baseline and 2723\u00a0\u00b1\u00a03435 and 2406\u00a0\u00b1\u00a03207\u00a0mm<jats:sup>3<\/jats:sup> after 24 and 48\u00a0weeks, respectively. At weeks 24 and 48, a significant (&gt;\u00a020%) tumour volume reduction was reported in 63% and 75% of patients, respectively. A reduction in the severity of symptoms of acromegaly was observed early in treatment and was maintained throughout the study period.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Octreotide LAR represents a viable alternative to surgery for primary treatment of acromegaly leading to a progressive regression of tumour volume, a sustained control of biochemical abnormalities and an adequate relief of symptoms of the disease.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2007.02825.x","type":"journal-article","created":{"date-parts":[[2007,5,6]],"date-time":"2007-05-06T17:58:16Z","timestamp":1178474296000},"page":"859-868","source":"Crossref","is-referenced-by-count":175,"title":["A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR<sup>\u00ae<\/sup> (long\u2010acting repeatable octreotide) in the primary therapy of patients with acromegaly"],"prefix":"10.1111","volume":"66","author":[{"given":"Moises","family":"Mercado","sequence":"first","affiliation":[]},{"given":"Fatima","family":"Borges","sequence":"additional","affiliation":[]},{"given":"Hakim","family":"Bouterfa","sequence":"additional","affiliation":[]},{"given":"Tien\u2010Chun","family":"Chang","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Chervin","sequence":"additional","affiliation":[]},{"given":"Andrew J.","family":"Farrall","sequence":"additional","affiliation":[]},{"given":"Attila","family":"Patocs","sequence":"additional","affiliation":[]},{"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Podoba","sequence":"additional","affiliation":[]},{"given":"Mitra","family":"Safari","sequence":"additional","affiliation":[]},{"given":"Joanna","family":"Wardlaw","sequence":"additional","affiliation":[]},{"name":"on behalf of the SMS995B2401 Study Group","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2007,4,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30204-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.12.3395"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb03789.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031199"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-011841"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021649"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02036"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.8370847.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.10.3419"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01863"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02430.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01734.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.6.2779"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2001-012012"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030110"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.01992.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-199207000-00004"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-6-1421"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.5.1604"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1680221"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2004.10.001"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2347"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02467.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.7.8665"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1093"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2466"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.2.781"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347378"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2007.02825.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2007.02825.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:08:45Z","timestamp":1697188125000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2007.02825.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,25]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1111\/j.1365-2265.2007.02825.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02825.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,25]]}}}